<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704912</url>
  </required_header>
  <id_info>
    <org_study_id>27184</org_study_id>
    <nct_id>NCT00704912</nct_id>
  </id_info>
  <brief_title>Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women</brief_title>
  <acronym>OWL-PCOS</acronym>
  <official_title>Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this three-armed randomized controlled trial is to establish the relative roles
      of treatment of hyperandrogenism versus obesity (as the largest modifiable factor
      contributing to insulin resistance) in treating infertility and improving pregnancy outcomes
      among obese PCOS women. The investigators hypothesize that the key to restoring ovulation
      leading to live birth is to correct hyperandrogenism with oral contraceptive pills, but the
      key to avoiding later pregnancy complications is to improve insulin sensitivity with weight
      loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility among
      women, and women with PCOS are at increased risk for pregnancy complications such as
      gestational diabetes and pre-eclampsia. Both hyperandrogenism (HA) and obesity exacerbated
      insulin resistance (IR) are characteristics of the syndrome, and are targets for treatment,
      but which should be the predominant focus is still unknown. Phase 1 of this study will be a
      randomized trial of three preconception interventions in infertile women with PCOS. The first
      arm will be a combined intervention of medication, meal replacements, and lifestyle
      modification to improve IR. Orlistat is a gastric lipase inhibitor that reduces the
      absorption of fat contained in a meal by about 30%. The second arm will be the use of a
      continuous OCP for 4 months to improve HA. Lo-Estrin 1/20 will be used in a continuous method
      for 4 months to suppress the ovary. The third arm is the combination of both to improve HA an
      IR. Phase II of this study will involve ovulation induction with clomiphene citrate with
      hopeful outcome of pregnancy. Finally, Phase III involve following the pregnancies for
      outcomes and complications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>Participants were followed for 4 months of attempted conception and those who conceived were then followed for the duration of their pregnancy, approximately 9 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovulation Rate</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Baseline, 4 months</time_frame>
    <description>Change from baseline to end of the 4-month intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Metabolic Syndrome</measure>
    <time_frame>Baseline, 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat/Meal Replacement/Lifestyle Modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Contraceptives (OCP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loestrin 1/20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle/OCP Combined</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat/Meal Replacement/Lifestyle Modification</intervention_name>
    <description>Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <other_name>Orlistat</other_name>
    <other_name>Alli</other_name>
    <other_name>Lifestyle Intervention</other_name>
    <other_name>Weight Loss</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loestrin 1/20</intervention_name>
    <description>Patients will be started on a low dose containing OCP for a continuous 4 month period.</description>
    <arm_group_label>Oral Contraceptives (OCP)</arm_group_label>
    <other_name>OCP</other_name>
    <other_name>Oral Contraceptive</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of treatments</intervention_name>
    <description>Medications will be administered as described for the other 2 arms.</description>
    <arm_group_label>Lifestyle/OCP Combined</arm_group_label>
    <other_name>Orlistat</other_name>
    <other_name>Alli</other_name>
    <other_name>OCP</other_name>
    <other_name>Oral Contraceptive</other_name>
    <other_name>Weight Loss</other_name>
    <other_name>Lifestyle Intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Couples Inclusion Criteria:

          -  Partner with sperm concentration of &gt;=14 million/mL in at least one ejaculate with
             motile sperm.

          -  Ability to have regular intercourse 2-3 times per week during the ovulation induction
             phase of study.

          -  At least one patent tube and normal uterine cavity as determined by sonohysterogram,
             hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years, or
             confirmation of a intrauterine pregnancy within the past 2 years.

          -  No previous sterilization procedures(vasectomy, tubal ligation) that have been
             reversed.

          -  Wanting to seek pregnancy.

        Inclusion Criteria:

          -  Chronic anovulation or oligomenorrhea defined as intermenstrual periods of &gt;= 45 days
             or a total of &lt;=8 periods per year.

          -  Hyperandrogenism will be an elevated total testosterone &gt;=50 ng/dL.

          -  Hirsutism determined by a modified Ferriman-Gallwey Score &gt;8.

          -  PCO on ultrasound (12 or more follicles measuring 2-9 mm in diameter).

          -  BMI &gt;=27 to &lt;=42.

          -  Normal EKG to rule out any abnormalities with the heart.

        Exclusion Criteria:

          -  Current pregnancy.

          -  Patients on oral contraceptives, depo progestins, or hormonal implants.

          -  Patients with hyperprolactinemia defined as two prolactin levels at least one week
             apart &gt;30 ng/mL.

          -  Patients with known 21-hydroxylase deficiency by a fasting 17-hydroxyprogesterone
             (17-OHP) level &lt;2 ng/mL and ACTH stimulation test as needed, or other enzyme
             deficiency.

          -  Patients with menopausal FSH levels &gt;20 mIU/mL.

          -  Patients with uncorrected thyroid disease (TSH &lt;0.45 mIU/ML or &gt;4.5 mIU/ML).

          -  Patients diagnosed with Type1 or Type II diabetes.

          -  Patients with liver disease defined as AST or ALT &gt;2 times normal or total bilirubin
             &gt;2.5 mg/dL.

          -  Patients with renal disease defined as BUN &gt;30 mg/dL or serum creatinine &gt;1.4 mg/dL.

          -  Patients with significant anemia (Hemoglobin &lt;10 mg/dL).

          -  Patients with a history of deep venous thrombosis, pulmonary embolus, or
             cerebrovascular accident.

          -  Patients with known heart disease that is likely to be exacerbated by pregnancy.

          -  Patients with a history of , or suspected cervical carcinoma, endometrial carcinoma,
             or breast carcinoma. A normal PAP smear or reassuring colposcopy based on current ACOG
             guidelines will be required.

          -  Patient with current history of alcohol abuse.

          -  Patients enrolled simultaneously into other investigative studies.

          -  Patients taking other medications know to affect reproductive function or metabolism.

          -  Patients with a suspected adrenal or ovarian tumor secreting androgens.

          -  Patients with suspected Cushing's syndrome.

          -  Patients who have undergone a bariatric surgery procedure in the recent past (&lt;12
             months).

          -  Patients with untreated poorly controlled hypertension defined as systolic blood
             pressure &gt;=150 mm Hg or average diastolic &gt;=100 mm Hg on three measurements obtained 5
             minutes apart. If treated, average systolic blood pressure &gt;= 140 mm Hg or average
             diastolic &gt;= 90 mm Hg.

          -  Patients with medical conditions that represent contraindications to orlistat, OCP,
             clomiphene, and/or pregnancy.

          -  Patients currently participating in lifestyle intervention program (Weight Watchers,
             Atkins Diet, Curves) or lost more than 5% body weight within the last 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Legro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Coutifaris, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universtiy of Pennsylvania, Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hmc.psu.edu</url>
    <description>Click here for more information about this study.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <results_first_submitted>November 13, 2015</results_first_submitted>
  <results_first_submitted_qc>November 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2015</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Richard S. Legro, M.D.</investigator_full_name>
    <investigator_title>Professor, Obstetrics and Gynecology and Public Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>217 subjects consented for the study, of which 149 were randomized to one of the 3 treatment groups. Sixty-eight subjects were not randomized because they withdrew prior to randomization or were determined ineligible during the screening process.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lifestyle Intervention</title>
          <description>Orlistat/Meal Replacement/Lifestyle Modification: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
        </group>
        <group group_id="P2">
          <title>Oral Contraceptives (OCP)</title>
          <description>Loestrin 1/20: Patients will be started on a low dose containing OCP (20 mcg ethinyl estradiol/1 mg norethindrone acetate daily) for a continuous 4 month period.</description>
        </group>
        <group group_id="P3">
          <title>Lifestyle/OCP Combined</title>
          <description>Combination of treatments: Medications will be administered as described for the other 2 arms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lifestyle Intervention</title>
          <description>Orlistat/Meal Replacement/Lifestyle Modification: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
        </group>
        <group group_id="B2">
          <title>Oral Contraceptives (OCP)</title>
          <description>Loestrin 1/20: Patients will be started on a low dose containing OCP (20 mcg ethinyl estradiol/1 mg norethindrone acetate daily) for a continuous 4 month period.</description>
        </group>
        <group group_id="B3">
          <title>Lifestyle/OCP Combined</title>
          <description>Combination of treatments: Medications will be administered as described for the other 2 arms.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="3.4"/>
                    <measurement group_id="B2" value="29.8" spread="3.7"/>
                    <measurement group_id="B3" value="28.7" spread="4.2"/>
                    <measurement group_id="B4" value="29.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 births</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0 births</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.0" spread="15.8"/>
                    <measurement group_id="B2" value="94.6" spread="14.4"/>
                    <measurement group_id="B3" value="95.2" spread="14.5"/>
                    <measurement group_id="B4" value="95.3" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="4.6"/>
                    <measurement group_id="B2" value="35.1" spread="4.2"/>
                    <measurement group_id="B3" value="35.5" spread="4.4"/>
                    <measurement group_id="B4" value="35.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolic Syndrome</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth Rate</title>
        <time_frame>Participants were followed for 4 months of attempted conception and those who conceived were then followed for the duration of their pregnancy, approximately 9 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lifestyle Intervention</title>
            <description>Orlistat/Meal Replacement/Lifestyle Modification: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptives (OCP)</title>
            <description>Loestrin 1/20: Patients will be started on a low dose containing OCP (20 mcg ethinyl estradiol/1 mg norethindrone acetate daily) for a continuous 4 month period.</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle/OCP Combined</title>
            <description>Combination of treatments: Medications will be administered as described for the other 2 arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Log-binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Log-binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Log-binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ovulation Rate</title>
        <time_frame>Up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lifestyle Intervention</title>
            <description>Orlistat/Meal Replacement/Lifestyle Modification: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptives (OCP)</title>
            <description>Loestrin 1/20: Patients will be started on a low dose containing OCP (20 mcg ethinyl estradiol/1 mg norethindrone acetate daily) for a continuous 4 month period.</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle/OCP Combined</title>
            <description>Combination of treatments: Medications will be administered as described for the other 2 arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Ovulation Rate</title>
          <units>total number of ovulations</units>
          <param>Number</param>
          <units_analyzed>Clomiphene Treatment Cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Clomiphene Treatment Cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Log-binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Log-binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Log-binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <description>Change from baseline to end of the 4-month intervention.</description>
        <time_frame>Baseline, 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lifestyle Intervention</title>
            <description>Orlistat/Meal Replacement/Lifestyle Modification: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptives (OCP)</title>
            <description>Loestrin 1/20: Patients will be started on a low dose containing OCP (20 mcg ethinyl estradiol/1 mg norethindrone acetate daily) for a continuous 4 month period.</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle/OCP Combined</title>
            <description>Combination of treatments: Medications will be administered as described for the other 2 arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>Change from baseline to end of the 4-month intervention.</description>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" lower_limit="-7.1" upper_limit="-5.3"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-2.0" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-6.1" lower_limit="-7.0" upper_limit="-5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Mean Change</param_type>
            <param_value>-5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>-3.8</ci_upper_limit>
            <estimate_desc>Lifestyle vs. OCP</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Mean Change</param_type>
            <param_value>-5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>-3.7</ci_upper_limit>
            <estimate_desc>Combined vs. OCP</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Mean Change</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Lifestyle vs. Combined</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Metabolic Syndrome</title>
        <time_frame>Baseline, 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lifestyle Intervention</title>
            <description>Orlistat/Meal Replacement/Lifestyle Modification: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptives (OCP)</title>
            <description>Loestrin 1/20: Patients will be started on a low dose containing OCP (20 mcg ethinyl estradiol/1 mg norethindrone acetate daily) for a continuous 4 month period.</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle/OCP Combined</title>
            <description>Combination of treatments: Medications will be administered as described for the other 2 arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Metabolic Syndrome</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metabolic Syndrome at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic Syndrome at End of Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparing change in prevalence of metabolic syndrome from baseline to the end of intervention.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>GEE</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>End of intervention compared to baseline.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparing change in prevalence of metabolic syndrome from baseline to the end of intervention.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>GEE</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>End of intervention compared to baseline</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparing change in prevalence of metabolic syndrome from baseline to the end of intervention.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>GEE</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>End of intervention compared to baseline</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>GEE</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>GEE</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>GEE</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lifestyle Intervention</title>
          <description>Orlistat/Meal Replacement/Lifestyle Modification: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.</description>
        </group>
        <group group_id="E2">
          <title>Oral Contraceptives (OCP)</title>
          <description>Loestrin 1/20: Patients will be started on a low dose containing OCP (20 mcg ethinyl estradiol/1 mg norethindrone acetate daily) for a continuous 4 month period.</description>
        </group>
        <group group_id="E3">
          <title>Lifestyle/OCP Combined</title>
          <description>Combination of treatments: Medications will be administered as described for the other 2 arms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Perforated appendix</sub_title>
                <description>Postpartum hospitalization for perforated appendix</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <description>Ectopic pregnancy requiring surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Preterm delivery</sub_title>
                <description>Preterm delivery of twins at 20 weeks: 1 live birth and 1 IUFD secondary to infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal uterine bleeding</sub_title>
                <description>Episode of abnormal uterine bleeding leading to ER visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Steatorrhea/Diarrhea</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gas/Bloating</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gas/Bloating</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness/Vertigo</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Visual Changes</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hot flushes</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Spotting in pregnancy</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginitis/Vulvitis</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal Dryness/Pain</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperemesis</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection in pregnancy</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness/Vertigo</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gas/Bloating</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Phase III After Conception: First trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gestational Diabetes</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Preterm Delivery</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Premature Rupture of Membranes</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infections</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Placental Abnormalities</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dental abscess</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dental, other</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Other specified disorders of biliary tract</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Breast lump</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginitis/Vulvitis</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection in pregnancy</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Incompetent cervix</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection of amniotic cavity</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness/Vertigo</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sleep apnea</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Edema localized</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <description>Phase III After Conception: Second and Third trimester</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pregnancy-induced Hypertension</sub_title>
                <description>Delivery and Postpartum</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pulmonary collapse</sub_title>
                <description>Delivery and Postpartum</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Postpartum depression</sub_title>
                <description>Delivery and Postpartum</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Postpartum infection</sub_title>
                <description>Delivery and Postpartum</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neonatal Jaundice</sub_title>
                <description>After 20 weeks pregnancy in fetus through neonatal period</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Intrauterine growth restriction</sub_title>
                <description>After 20 weeks pregnancy in fetus through neonatal period</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neonatal infection</sub_title>
                <description>After 20 weeks pregnancy in fetus through neonatal period</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Other complication of infant after delivery</sub_title>
                <description>After 20 weeks pregnancy in fetus through neonatal period</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Swings</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Pain</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abnormal uterine bleeding</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vaginitis/Vulvitis</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hot flushes</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vaginal Dryness/Pain</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infections</sub_title>
                <description>Phase I Intervention</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infections</sub_title>
                <description>Phase II Ovulation Induction</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard S. Legro, M.D.</name_or_title>
      <organization>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</organization>
      <phone>717-531-8478</phone>
      <email>rsl1@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

